Jul 25 |
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
|
Jul 25 |
Cerevel gains as AbbVie says it expects deal to close soon (update)
|
Jul 25 |
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
Jul 25 |
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
|
Jul 25 |
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
|
Jul 25 |
AbbVie raises outlook as new immunology drugs offset Humira impact
|
Jul 25 |
AbbVie in charts: Skyrizi, Rinvoq sales jump, while Humira revenue falls ~30% Y/Y in Q2
|
Jul 25 |
Earnings summary: AbbVie reports mixed Q2 results; raises FY24 EPS outlook
|
Jul 25 |
Is AbbVie the Best Dividend Stock for You?
|
Jul 25 |
AbbVie: Q2 Earnings Snapshot
|